Predicted Trait | |
Reported Trait | Non-alcoholic fatty liver disease |
Mapped Trait(s) | non-alcoholic fatty liver disease (EFO_0003095) |
Score Construction | |
PGS Name | PRS-5 |
Development Method | |
Name | 4 variants from Dongiovanni et al (PGS000865) |
Parameters | Adjusted for the addition of rs72613567 (HSD17B13) |
Variants | |
Original Genome Build | NR |
Number of Variants | 5 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000215 |
Citation (link to publication) | Bianco C et al. J Hepatol (2020) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
Europe PMC: 18820647 |
1,032 individuals | African American or Afro-Caribbean | DaHS |
Europe PMC: 18820647 |
696 individuals | European | DaHS |
Europe PMC: 18820647 |
383 individuals | Hispanic or Latin American | DaHS |
GWAS Catalog: GCST001008 Europe PMC: 21423719 |
7,176 individuals | European | AGES, AMISH, FHS, FamHS |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
2,448 individuals | African American or Afro-Caribbean | DaHS |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
1,365 individuals | European | DaHS |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
753 individuals | Hispanic or Latin American | DaHS |
GWAS Catalog: GCST003153 Europe PMC: 26482880 |
2,138 individuals | European | NR |
GWAS Catalog: GCST001928 Europe PMC: 23535911 |
1,326 individuals | East Asian | NR |
Europe PMC: 29562163 |
46,544 individuals, 42.0 % Male samples |
European | MyCode |
GWAS Catalog: GCST010096 Europe PMC: 24531328 |
141 individuals | Not reported | DaHS |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
Europe PMC: 29280273 |
2,736 individuals | European, African American or Afro-Caribbean, Hispanic or Latin American | DaHS | — | — | — | — | This dataset was used to obtain effect weights for 4 of the 5 SNPs within PRS-5 |
— | 2,532 individuals | Not reported | NR | — | — | — | — | This dataset was used to obtain the effect weight for rs72613567 (HSD17B13) within PRS-5 |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM002418 | PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Cirrhosis | OR: 4.4 [3.5, 5.6] | — | — | — | — |
PPM002420 | PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Cirrhosis | OR: 4.5 [3.6, 5.7] | — | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | — |
PPM002432 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Severe fibrosis in individuals within stage F3-F4 of fatty liver disease | OR: 9.4 [5.4, 16.2] | — | — | Age, sex, body mass index, type 2 diabetes | — |
PPM002419 | PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 11.9 [6.6, 21.3] | — | — | — | — |
PPM002421 | PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 11.7 [6.54, 21.0] | — | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | — |
PPM002422 | PSS001096| European Ancestry| 364,048 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 4.8 [2.6, 8.9] | — | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre, diagnosis of cirrhosis | — |
PPM002428 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Fatty liver disease | OR: 9.0 [6.0, 13.4] | — | — | — | — |
PPM002429 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Severe fibrosis in individuals within stage F3-F4 of fatty liver disease | OR: 12.6 [8.2, 19.3] | — | — | — | — |
PPM002430 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 9.1 [5.2, 16.0] | — | — | — | — |
PPM002431 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Fatty liver disease | OR: 10.7 [6.6, 17.3] | — | — | Age, sex, body mass index, type 2 diabetes | — |
PPM002433 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 3.3 [1.6, 6.9] | — | — | Age, sex, body mass index, type 2 diabetes | — |
PPM002440 | PSS001094| European Ancestry| 2,564 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 2.9 [2.1, 3.8] | AUROC: 0.65 | — | Age, sex, body mass index, type 2 diabetes | Only 2,245 participants were available for this analysis. |
PPM002443 | PSS001097| European Ancestry| 356,943 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 3.4 [2.5, 4.7] | AUROC: 0.63 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-5 was treated as a binary variable with a cutoff of ≥0.495 |
PPM002445 | PSS001101| European Ancestry| 355,450 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma in individuals with no cirrhosis | OR: 1.9 [1.1, 3.2] | AUROC: 0.54 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-5 was treated as a binary variable with a cutoff of ≥0.495 |
PPM002447 | PSS001098| European Ancestry| 85,890 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma in individuals with a body mass index ≥30 | OR: 5.5 [3.6, 8.5] | AUROC: 0.69 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-5 was treated as a binary variable with a cutoff of ≥0.495 |
PPM002449 | PSS001103| European Ancestry| 25,039 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma in individuals with type 2 diabetes | OR: 4.6 [2.9, 7.3] | AUROC: 0.71 | — | Age, sex, body mass index, type 2 diabetes, PCs(1-10), array batch, assessment centre | PRS-5 was treated as a binary variable with a cutoff of ≥0.495 |
PPM002451 | PSS001095| Ancestry Not Reported| 429 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 8.61 [3.31, 22.37] | AUROC: 0.65 | — | — | — |
PPM002453 | PSS001095| Ancestry Not Reported| 429 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 6.36 [1.67, 24.31] | — | — | Age, sex, body mass index, type 2 diabetes | — |
PPM002455 | PSS001095| Ancestry Not Reported| 429 individuals |
PGP000215 | Bianco C et al. J Hepatol (2020) |
Reported Trait: Hepatocellular carcinoma | OR: 2.4 [1.19, 4.83] | — | — | — | PRS-5 was treated as a binary variable with a cutoff of ≥0.495 |
PPM019102 | PSS011182| European Ancestry| 381,825 individuals |
PGP000505 | Liu Z et al. Liver Int (2023) |Ext. |
Reported Trait: Non-alcoholic fatty liver disease | — | — | p-value (inferior to): 0.001 | age, sex, ethnicity, Townsend deprivation index (quintiles), education level, household income, employment status, self-reported smoking status, self-reported frequency of alcohol intake, sedentary behaviour, body mass index, baseline diabetes, baseline hypertension, serum triglyceride level, C-reactive protein level, and eGFR | — |
PPM019103 | PSS011182| European Ancestry| 381,825 individuals |
PGP000505 | Liu Z et al. Liver Int (2023) |Ext. |
Reported Trait: Severe liver disease | — | — | p-value (inferior to): 0.001 | age, sex, ethnicity, Townsend deprivation index (quintiles), education level, household income, employment status, self-reported smoking status, self-reported frequency of alcohol intake, sedentary behaviour, body mass index, baseline diabetes, baseline hypertension, serum triglyceride level, C-reactive protein level, and eGFR | — |
PPM019104 | PSS011182| European Ancestry| 381,825 individuals |
PGP000505 | Liu Z et al. Liver Int (2023) |Ext. |
Reported Trait: Serum uric acid levels x PRS interaction for liver disease | HR: 1.03 [1.01, 1.05] | — | — | age, sex, ethnicity, Townsend deprivation index (quintiles), education level, household income, employment status, self-reported smoking status, self-reported frequency of alcohol intake, sedentary behaviour, body mass index, baseline diabetes, baseline hypertension, serum triglyceride level, C-reactive protein level, and eGFR | — |
PPM019105 | PSS011182| European Ancestry| 381,825 individuals |
PGP000505 | Liu Z et al. Liver Int (2023) |Ext. |
Reported Trait: Serum uric acid levels x PRS interaction for severe liver disease | HR: 1.06 [1.03, 1.1] | — | — | age, sex, ethnicity, Townsend deprivation index (quintiles), education level, household income, employment status, self-reported smoking status, self-reported frequency of alcohol intake, sedentary behaviour, body mass index, baseline diabetes, baseline hypertension, serum triglyceride level, C-reactive protein level, and eGFR | — |
PPM019101 | PSS011182| European Ancestry| 381,825 individuals |
PGP000505 | Liu Z et al. Liver Int (2023) |Ext. |
Reported Trait: Liver disease | — | — | p-value (inferior to): 0.001 | age, sex, ethnicity, Townsend deprivation index (quintiles), education level, household income, employment status, self-reported smoking status, self-reported frequency of alcohol intake, sedentary behaviour, body mass index, baseline diabetes, baseline hypertension, serum triglyceride level, C-reactive protein level, and eGFR | — |
PPM021276 | PSS011674| European Ancestry| 5,209 individuals |
PGP000622 | Åberg F et al. Liver Int (2023) |Ext. |
Reported Trait: Liver-related hospitalization, hepatocellular cancer or liver-related death | HR: 5.05 [1.55, 16.5] | — | — | Enhanced liver fibrosis (ELF) test, chronic liver disease (CLivD) score | PGS did not increase predictive performance over ELF test + CLivD score |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS001103 | All individuals had type 2 diabetes (T2D). Diabetes was defined as individuals having either of following criteria: 1) self-reported type 2 or unspecified diabetes (codes 1220 and 1223 in data-field 20002); 2) ICD10 diagnoses codes E11 and E14 (data-field 41270); 3) insulin treatment or use of oral glucose lowering drugs (data-fields 6153, 6177 and 20003); 4) serum glucose level ≥11.1 mmol/L (200mg/dL); 5) HbA1c ≥ 48 mmol/mol (6.5%). Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
PSS011674 | — | — | [
|
— | European (Finnish) |
— | Health2000 | — |
PSS011182 | — | — | 381,825 individuals | — | European | — | UKB | — |
PSS001094 | Cases were individuals with liver disease. Of the 1,699 cases, 1,473 had fatty liver disease (FLD) whilst 226 had hepatocellular carcinoma (HCC). Of the 1,473 individuals with FLD, 297 had severe fibrosis and were therefore classified as being within stage 3-4 of FLD. Severe fibrosis was defined in the presence of histological fibrosis F3-F4 (when liver biopsy was available) or in presence of clinical, endoscopic or radiological signs of portal hypertension or cirrhosis, or liver stiffness ≥8.4 kPa evaluated by Fibroscan. Diagnosis of HCC was based on EASL-EORTC Clinical Practice Guidelines. | — | [ ,
57.76 % Male samples |
— | European | — | NR | Cases were obtained from the Nonalcoholic Fatty Liver Disease (NAFLD) Case-Control Cross-Sectional Cohort. |
PSS001095 | All individuals had liver disease. Of the 158 cases, 72 had cirrhosis whilst 84 had hepatocellular cancer. Diagnosis of HCC was based on EASL-EORTC Clinical Practice Guidelines | — | [ ,
43.59 % Male samples |
— | Not reported | — | NR | — |
PSS001096 | Cases were individuals with liver disease. Of the 1,628 cases, 1,426 individuals had cirrhosis whilst 202 had hepatocellular cancer (HCC). Cirrhosis was defined as ICD-10 codes I85.0, I85.9, K70.3, K70.4, K72.1, K74.1, K74.2, K74.6, K76.6, K76.7 using hospitalization records (data-field 41270). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [ ,
46.22 % Male samples |
— | European | — | UKB | — |
PSS001097 | Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
PSS001098 | All individuals had a body mass index ≥30. Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |
PSS001101 | All individuals had no diagnosis of cirrhosis. Cases were individuals with hepatocellular cancer (HCC). HCC was defined by combining International Classification of Diseases, Tenth Revision (ICD-10) code C22.0 from both UK cancer registry (data-field 40006), and hospitalization records (data-field 41270). | — | [
|
— | European | — | UKB | — |